BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Covington
Fuji
AstraZeneca
Healthtrust
Fish and Richardson
Teva
Novartis
Cantor Fitzgerald

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,333,045

« Back to Dashboard

Which drugs does patent 6,333,045 protect, and when does it expire?

Patent 6,333,045 protects ZYMAR and is included in one NDA.

Protection for ZYMAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixteen patent family members in fifteen countries.
Summary for Patent: 6,333,045
Title: Aqueous liquid pharmaceutical composition comprised of gatifloxacin
Abstract:There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazi nyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
Inventor(s): Yasueda; Shinichi (Kobe, JP), Inada; Katsuhiro (Kobe, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (Osaka, JP) Kyorin Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:09/529,882
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 6,333,045

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan ZYMAR gatifloxacin SOLUTION/DROPS;OPHTHALMIC 021493-001 Mar 28, 2003 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,333,045

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10/235432Aug 21, 1998
PCT Information
PCT FiledAugust 20, 1999PCT Application Number:PCT/JP99/04483
PCT Publication Date:March 02, 2000PCT Publication Number: WO00/10570

International Patents Family Members for US Patent 6,333,045

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 5138128 ➤ Subscribe
Hong Kong 1029934 ➤ Subscribe
Spain 2264266 ➤ Subscribe
European Patent Office 1025846 ➤ Subscribe
Denmark 1025846 ➤ Subscribe
Germany 69932313 ➤ Subscribe
China 1133432 ➤ Subscribe
China 1275081 ➤ Subscribe
Canada 2307632 ➤ Subscribe
Brazil PI9906735 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cerilliant
Citi
Queensland Health
Dow
Cipla
McKinsey
Fish and Richardson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot